Auteur/autrice : oxeltis

Grant will fund three-year EPIGENEXT joint project aimed at developing first-in-class therapy for diffuse large B-cell lymphoma Oss, the Netherlands and Montpellier, France, June 8, 2022 – Lead Pharma, a (...)

Organized by the Asian Federation for Medicinal Chemistry (AFMC), AIMECS 2021 (AFMC International Medicinal Chemistry Symposium 2021) is a major event in medicinal chemistry in Asia.Oxeltis, a medicinal chemistry service (...)

Oxeltis is happy to participate and sponsor IS3NA-IRT 2021 Virtual meeting. Looking forward contacting you about your nucleos(t)ides medchem and custom synthesis programs.   https://www.is3na.org/events-1/2021-virtual-symposium

Oxeltis est heureux de participer et de sponsoriser le GECO 2021. Retrouvez-nous pour tous besoins de ressources externes sur vos programmes de chimie médicinale et de synthèse à façon. https://geco61.sciencesconf.org/

Oxeltis' scientists are participating to RICT 2021, lets connect and interact ! Why not planning a virtual meeting at contact@oxeltis.com https://www.rict2021.org/

https://resiconference.com Connect with Oxeltis at Resi Conference, 8-10 June 2021  #medicinalchemistry #smallmolecules #antivirals #medchemservices #networkinghttps://resiconference.com

Dr Stéphane Salamone and Dr Olivier Lavergne will be instrumental in boosting additional lab and medchem capabilities at the company Montpellier, France, November 9, 2020 – Oxeltis, a medicinal chemistry (...)

At Oxeltis, we are committed to continuing our medicinal chemistry research services during the Sars-Cov 2 outbreak, with respect to our staff’s safety and in accordance with the rules put in (...)

For the second year, Oxeltis is participating to the Medicinal Chemistry Symposium organized by the Pharmaceutical Society of Japan. Please visit us at Oxeltis booth #9 to talk about your (...)

Oxeltis is pleased to announce to its customers and R&D partners the renewal of its agreement for R&D tax credit (agrément Crédit Impôt Recherche) by the French Ministry of Higher (...)